Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Investing.com - Canaccord Genuity raised its price target on Guardant Health (NASDAQ:GH) to $100 from $75 while maintaining a Buy rating on the stock, following the company’s strong third-quarter results. The new target represents significant upside from the current price of $72.27, with GH trading near its 52-week high of $73.31. According to InvestingPro data, the stock has delivered an impressive 213.26% return over the past year.
Guardant Health reported its Q3 2025 results on Wednesday, which exceeded both Canaccord’s estimates and FactSet consensus. The performance was attributed to broad-based growth in both revenue and volume, with Shield revenue particularly outperforming expectations. This continues the company’s strong growth trajectory, with InvestingPro showing revenue growth of 28.74% over the last twelve months.
The healthcare company increased its 2025 revenue guidance, now projecting approximately 31% year-over-year growth. Guardant also raised its annual revenue and volume guidance specifically for its Shield test. This outlook exceeds analyst expectations, with the current analyst consensus rating at 1.35 (Strong Buy) and price targets ranging from $47 to $85.
Guardant Health achieved cash flow breakeven excluding screening in Q3 2025, reaching this milestone one quarter ahead of schedule. The company continues to anticipate Shield inclusion into American Cancer Society guidelines and Advanced Diagnostic Laboratory Test status for its Reveal test in the near term. The company’s solid financial position is reflected in its healthy current ratio of 3.71, indicating liquid assets comfortably exceed short-term obligations.
Canaccord’s price target increase was driven by projected higher revenue growth and operating margin expansion in the later years of its 10-year discounted cash flow model, with the firm stating that Guardant shares "remain undervalued" due to its "impressive therapy selection execution" and "improving financial profile." However, InvestingPro’s Fair Value assessment suggests the stock may be currently overvalued after its remarkable 136.56% gain year-to-date. Discover more insights in Guardant Health’s comprehensive Pro Research Report, available with an InvestingPro subscription.
In other recent news, Guardant Health reported strong third-quarter 2025 earnings, surpassing market expectations. The company achieved an earnings per share of -$0.39, significantly better than the forecasted -$0.79, and reported revenue of $265.2 million, exceeding projections of $235.64 million. This performance resulted in a 12.54% revenue surprise. Following these results, BTIG raised its price target for Guardant Health to $100 from $80, maintaining a Buy rating. Wolfe Research also increased its price target to $90 from $75, citing the company’s ownership of key cancer screening and detection technologies. These developments reflect the company’s ongoing advancements in blood-based colorectal cancer screening and other diagnostic technologies. Both research firms have expressed continued confidence in Guardant Health’s potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.